相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects
Jason R. B. Dyck et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2022)
Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation
Detmar Kolijn et al.
CARDIOVASCULAR RESEARCH (2021)
Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure
Hideo Nambu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Ageing-associated increase in SGLT2 disrupts mitochondrial/sarcoplasmic reticulum Ca2+homeostasis and promotes cardiac dysfunction
Yusuf Olgar et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function
Yasuhiro Maejima
FRONTIERS IN CARDIOVASCULAR MEDICINE (2020)
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
Chenguang Li et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction
Salva R. Yurista et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance
Alvaro Garcia-Ropero et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Leptin's hunger-suppressing effects are mediated by the hypothalamic-pituitary-adrenocortical axis in rodents
Rachel J. Perry et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes
Peili Wu et al.
HORMONE AND METABOLIC RESEARCH (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy
Aya Shiraki et al.
CARDIOVASCULAR DIABETOLOGY (2019)
SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
Carolyn S. P. Lam et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Calcium Signaling and Reactive Oxygen Species in Mitochondria
Edoardo Bertero et al.
CIRCULATION RESEARCH (2018)
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma et al.
DIABETOLOGIA (2018)
Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet
Susumu Takagi et al.
JOURNAL OF DIABETES INVESTIGATION (2018)
Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission
Hao Zhou et al.
REDOX BIOLOGY (2018)
A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
Aysegul Durak et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
Laween Uthman et al.
DIABETOLOGIA (2018)
Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes
Julian Mustroph et al.
ESC HEART FAILURE (2018)
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
Antonius Baartscheer et al.
DIABETOLOGIA (2017)
Pre-ischaemic mitochondrial substrate constraint by inhibition of malate-aspartate shuttle preserves mitochondrial function after ischaemia-reperfusion
Nichlas Riise Jespersen et al.
JOURNAL OF PHYSIOLOGY-LONDON (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Empagliflozin's Fuel Hypothesis: Not so Soon
Gary D. Lopaschuk et al.
CELL METABOLISM (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Impaired cardiac mitochondrial oxidative phosphorylation and enhanced mitochondrial oxidative stress in feline hypertrophic cardiomyopathy
Liselotte B. Christiansen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2015)
Leptin resistance in obesity: An epigenetic landscape
Ana B. Crujeiras et al.
LIFE SCIENCES (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2014)
Adverse Bioenergetic Consequences of Na+-Ca2+ Exchanger-Mediated Ca2+ Influx in Cardiac Myocytes
Michael Kohlhaas et al.
CIRCULATION (2010)
Oxidative stress causes heart failure with impaired mitochondrial respiration
Hidetoshi Nojiri et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
分享论文
